STOCK TITAN
  1. Home
  2. News
  3. LH

Laboratory Corp. Of America Holdings - LH STOCK NEWS

Welcome to our dedicated news page for Laboratory Of America Holdings (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Laboratory Of America Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Laboratory Of America Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Laboratory Of America Holdings's position in the market.

News
Labcorp Announces 2024 First Quarter Results
Rhea-AI Summary
Labcorp announced its 2024 first quarter results, reporting a revenue of $3.18 billion, up 4.6% from last year. The company raised its full-year adjusted EPS guidance to $14.45 to $15.35. Labcorp made significant acquisitions, expanded its test menu, and advanced growth initiatives. The company also launched innovative tests, received FDA authorization, and announced a new holding company structure. Labcorp's Diagnostics Laboratories revenue increased by 4.1%, and Biopharma Laboratory Services revenue grew by 7.5%. The company updated its 2024 guidance, expecting revenue growth between 4.8% to 6.4% and adjusted EPS of $14.45 to $15.35.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Labcorp Announces Winning Bid for Select Assets of Invitae
Rhea-AI Summary
Labcorp, a global leader in laboratory services, has won the bid for select assets of Invitae, a medical genetics company. The transaction, awaiting court approval on May 6, 2024, is valued at $239 million and is expected to generate $275-$300 million in annual revenue, primarily in oncology and rare diseases testing. The deal is set to close in the third quarter of 2024, pending regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Invitae Enters into Agreement with Labcorp for Sale of Business
Rhea-AI Summary
Invitae, a leading medical genetics company, has entered into an agreement with Labcorp for the sale of its business. Labcorp, a global leader in laboratory services, has been selected as the winning bidder in a court-supervised sale process under Section 363 of the U.S. Bankruptcy Code. The $239 million cash bid includes the acquisition of substantially all of Invitae's assets, ensuring business continuity for customers, partners, and employees. The sale is subject to court and regulatory approvals, with completion expected in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
Rhea-AI Summary
Labcorp introduces the first nationwide GFAP blood biomarker test for early detection of neurodegenerative diseases and brain injuries, expanding their neurology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
News
Labcorp Declares Quarterly Dividend
Rhea-AI Summary
Labcorp (LH) declares a cash dividend of $0.72 per share of common stock, payable on June 12, 2024, to stockholders of record as of May 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
dividends
-
News
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit
Rhea-AI Summary
Labcorp receives FDA Emergency Use Authorization for the first at-home Mpox PCR Test Collection Kit, aiding in the detection of monkeypox virus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
News
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs
Rhea-AI Summary
Labcorp (LH) expands its precision oncology portfolio to advance cancer research, introducing Labcorp Plasma Detect and enhancing Labcorp Plasma Complete. The company invests in cell and gene therapy, supporting FDA-approved CAR T-cell therapies and gene replacement therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
clinical trial
-
News
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Rhea-AI Summary
Labcorp launches Labcorp Plasma Detect, the first clinically validated MRD solution for early-stage colon cancer. The solution aims to identify patients at risk of recurrence after surgery or chemotherapy, enhancing Labcorp's precision oncology offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
clinical trial
-
News
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
Rhea-AI Summary
Labcorp to present innovative research on cancer biomarkers and personalized medicine at the AACR Annual Meeting, showcasing commitment to advancing cancer care and precision oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
conferences
News
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp
Rhea-AI Summary
Xcell Biosciences Inc. deepens its partnership with Labcorp through new financing, beta access to clinical manufacturing instruments, and AACR data presentations. Labcorp increases its strategic investment in Xcellbio, joins Xcellbio's board of directors, and participates in the beta program for AVATAR™ instruments. Xcellbio and Labcorp will jointly present results at the AACR annual meeting, showcasing their cell and gene therapy collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
Stock LH logo
Laboratory Corp. Of America Holdings

NYSE:LH

LH Rankings

#565 Ranked by Market Cap
#1736 Ranked by Stock Gains
#1661 Ranked by Dividends

LH Stock Data

17.31B
83.67M
0.34%
98.27%
2.29%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
US
Burlington

About LH

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.